Project Grant R37CA303990
Award Date 9/12/25
Completion Date 8/31/30
Dollars Obligated $629K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, is funded under the Cancer Research Manpower (CFDA 93.398) program. The $216,460 award to Case Western Reserve University will support research to investigate the epigenetic drivers of lung metastasis in osteosarcoma. The project aims to study the key transcription factors and chromatin state changes that enable lung colonization by osteosarcoma cells, with the goal of...
- This Project Grant award, totaling $102,984, was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to support research conducted by The Trustees of Columbia University in the City of New York. The research aims to dissect the novel role of Focal Adhesion Kinase (FAK) in modulating immunity during metastatic reactivation and progression of cancer. The key objectives are to investigate how FAK suppresses the STING innate immunity pathway, thereby enabling immune...
- This $452,549 Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Emory University on March 1, 2025. The grant is funding research to model and target the intrinsic and extrinsic molecular features of Myc-driven osteosarcoma, the most common bone tumor in pediatric patients. The research aims to comprehensively understand the tumor biology and identify effective therapeutic approaches, given the poor prognosis for patients with Myc-amplified...
- This federal Project Grant award of $1,033,055.00 was provided by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The funding supports research aimed at understanding and targeting the mechanisms of cancer metastasis. The project, titled "Targeting Cancer Metastasis by Inhibiting Curvature-Induced Kinase Activation," seeks to unravel the molecular pathways underlying how cancer cells acquire the...
- This $540,090 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research on epigenetic analysis of osteosarcoma. The key objectives are to: 1) Define the core regulatory circuitry driving epigenetic heterogeneity in osteosarcoma and identify transcription factor vulnerabilities for osteosarcoma subtypes using in vitro and in vivo CRISPR...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $210,789 to Texas A&M University System Health Science Center to conduct research on a DKK-1 targeting antisense therapy for osteosarcoma. The research aims to characterize the effects of a canine version of the DKK-1 inhibiting antisense therapy (cDKKMO) on canine osteosarcoma cell lines and patient-derived xenografts, as well as test the therapy's ability to inhibit tumor...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Houston System to investigate the role of the TAK1 signaling protein in the development and growth of rhabdomyosarcoma, a type of cancerous sarcoma. The $658,223 award, running from February 1, 2025 to January 31, 2030, will fund studies to examine the molecular mechanisms by which TAK1 drives rhabdomyosarcoma tumorigenesis and inhibits myogenic...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $514,405.00 in funding to Sanford Research to investigate the roles of cancer-dependent skeletal genes and pathways in the development and progression of osteosarcoma, a deadly bone cancer that primarily affects children. The research aims to elucidate the cancer dependency pathways involving the tumor protein p53 and Notch signaling that regulate premalignant osteoblasts and the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $465,020 to the University of Maryland, Baltimore (UMB) to conduct research on the mechanisms by which chemotherapy can inadvertently promote metastasis in epithelial ovarian cancer. The research aims to determine how clinically approved chemotherapies activate tumor-associated membrane-anchored serine proteases (MASPs) in a way that potentiates tumor dissemination and metastatic...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Beckman Research Institute of the City of Hope to investigate the role of IL-6/STAT3 signaling in the progression and metastasis of CIC-DUX4 fusion-positive sarcomas. The $593,028 award, effective April 3, 2025 through March 31, 2030, will fund studies to determine whether targeting the IL-6/STAT3 pathway can block tumor growth, metastasis, and immunosuppression...